Welcome to our dedicated page for NOVELSTEM INTL news (Ticker: NSTM), a resource for investors and traders seeking the latest updates and insights on NOVELSTEM INTL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NOVELSTEM INTL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NOVELSTEM INTL's position in the market.
NovelStem International Corp. (NSTM) announced significant developments and a strategic repositioning focused on seeking merger opportunities. The company's 29.5% interest in NewStem Ltd. has been impacted as NewStem ceased operations and was liquidated, with its technology reverting to Yissum. NovelStem retains rights to share up to $3.75M from future monetization of NewStem's IP platform.
The company has successfully extinguished $3.0M in litigation funding debt through the sale of its 50% stake in Netco Partners. Additionally, NovelStem is in discussions to reduce approximately $1.7M of notes payable and convertible debt. The company has also satisfied a $650,000 derivative liability guarantee. Directors and officers currently own about 48% of total shares, with 46,881,475 shares outstanding and 9.4M in options and warrants.
FAQ
What is the current stock price of NOVELSTEM INTL (NSTM)?
